35 Gatehouse Drive A-2
About Morphic TherapeuticMorphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.
CEO: Praveen Tipirneni, M.D.
Chief Development Officer: Alex Lugovskoy, Ph.D.
Vice President of Chemistry: Blaise Lippa, Ph.D.
Vice President of Finance and Operations: Robert Farrell, CPA
86 articles with Morphic Therapeutic
AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic D...
10/18/2018Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept
Series B financing led by Omega Funds and Novo Holdings
Biotechnology company Morphic Therapeutic has just publicized their completion of a successful $80 million Series B financing meant to support their two lead programs in developing modern oral integrin therapies, as well as further other clinic programs.
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.